Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company today and set a price target of $98.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tim Anderson has given his Buy rating due to a combination of factors including Merck & Company’s solid financial performance and promising future prospects. The company’s Q3 results showed a slight revenue increase and a notable earnings per share growth, which were supported by disciplined cost management and favorable tax conditions. Additionally, the company’s 2025 guidance was adjusted upwards, reflecting confidence in its future earnings potential.
Moreover, Merck’s pipeline developments, such as the advancement of MRK-8478 to phase 3 and the improved DFS in Welireg, contribute positively to its long-term growth outlook. Despite some uncertainties related to Keytruda’s competition and sector challenges, Anderson believes that the stock is undervalued given its growth potential, justifying the Buy rating with a price objective of $98.00 USD.
In another report released on October 13, Leerink Partners also maintained a Buy rating on the stock with a $107.00 price target.